QPPV.COM

Antidepressant Safety in 2026: Persistent Sexual Dysfunction, Suicidality and the MHRA's New Risk-Minimisation Measures

In October 2026 the MHRA strengthened how antidepressant risks are communicated in the UK after a multi-year review involving patients, families, experts and the Commission on Human Medicines. This article explains the regulatory history, the evidence and uncertainty around suicidal thoughts and behaviours and persistent sexual dysfunction, the new risk-minimisation measures, and what the changes mean for pharmacovigilance systems, marketing authorisation holders and effectiveness evaluation.

Take test

Antidepressant Safety in 2026: Persistent Sexual Dysfunction, Suicidality and the MHRA's New Risk-Minimisation Measures

On 15 October 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) announced strengthened safety communications for antidepressants. The measures include a new boxed warning in patient information leaflets (PILs) directing attention to suicidal thoughts and behaviours, a portable patient card, revised wording on sexual dysfunction that may persist after treatment is stopped, and a new safety leaflet planned for 2027. The term post-SSRI sexual dysfunction (PSSD) is being added to the PILs of relevant antidepressants where persistent sexual dysfunction is already recognised or where the review identified a potential association. [1,2]

The regulatory action is important, but it needs to be described precisely. The MHRA did not announce that suicidal thoughts, suicidal behaviours or persistent sexual dysfunction were newly discovered adverse reactions in October 2026. The agency explicitly presented the measures as strengthened communication of recognised risks following a review of whether existing warnings were sufficiently clear, prominent and actionable. [1,2]

The episode is therefore a useful pharmacovigilance case study in risk minimisation rather than simply signal detection. It shows how a regulator can revisit the effectiveness of existing safety communication when the underlying risk is already known, use patient and family experience alongside scientific evidence, redesign patient-facing materials, coordinate messages across the healthcare system, and plan studies to evaluate whether the intervention actually improves safety.

What Changed in October 2026

The MHRA announced several linked measures. Their purpose is to improve recognition, understanding and action rather than merely add more text to already lengthy product information.

Measure Intended function
Boxed warning in the PIL Make the warning on thoughts of self-harm and suicidal behaviour easier to find
Portable patient card Reinforce key safety messages and tell patients where to seek help
Revised wording on persistent sexual dysfunction Explicitly acknowledge that sexual dysfunction can continue after treatment is stopped and, for relevant medicines, include the term PSSD
Safety ancillary leaflet Provide broader information on benefits, risks and alternatives to support treatment discussions; planned for 2027
Wider healthcare-system alignment Promote consistent safety messaging across MHRA materials, BNF, NICE guidance and relevant professional communications
Effectiveness monitoring Use pharmacovigilance and proposed observational research to assess the impact of the regulatory action

The Drug Safety Update advises healthcare professionals to discuss suicidal thoughts and behaviours when antidepressants are started, doses are changed, or at review; to discuss the possibility of persistent sexual dysfunction with relevant medicines; and to report suspected adverse reactions through the Yellow Card scheme. [1]

For pharmacovigilance, the significant point is that these measures form a system of communication controls. The PIL is only one layer. Patient cards, clinician discussions, clinical guidance, ancillary material, spontaneous reporting and post-implementation research are intended to work together.

The Review Was About Communication Effectiveness

The Commission on Human Medicines (CHM) Expert Working Group on Antidepressant Risk Minimisation was established after concerns from patients and families that existing information did not adequately communicate the risks of suicidal thoughts and behaviours. The review later expanded to include sexual dysfunction that can continue after stopping antidepressants. [2,4]

The MHRA Public Assessment Report states that the review considered the views and experiences of patients and families, scientific literature, Yellow Card reports, regulatory history and possible additional risk-minimisation options. The Expert Working Group met during 2024 and 2025, and the CHM considered its recommendations in September 2025. In 2026 the MHRA further tested proposed patient-facing wording with a patient focus group before finalising the updated position. [2]

This history matters because it demonstrates a different pharmacovigilance question from the usual “is this adverse event caused by the medicine?” question. Here the central question was closer to:

Are recognised risks being communicated effectively enough for patients and healthcare professionals to understand them and act appropriately?

That is a risk-minimisation effectiveness question.

An MAH or regulator can have accurate product information and still have an ineffective safety intervention if the information is difficult to find, poorly understood, delivered too late in the treatment pathway, inconsistent across materials, or not reinforced in clinical practice.

Regulatory Timeline

The 2026 measures sit within a much longer regulatory history.

The regulatory lesson is that safety communication can evolve even when the underlying risk assessment does not change dramatically. A mature pharmacovigilance system therefore needs to monitor not only whether a risk is known, but whether the risk-minimisation strategy remains fit for purpose.

Suicidal Thoughts and Behaviours: Known Risk, Stronger Communication

The MHRA review did not identify substantial new primary evidence since 2019 that changed the established regulatory understanding of suicidal thoughts and behaviours for the 28 antidepressants reviewed. The Public Assessment Report states that the available evidence was broadly consistent with the existing regulatory position. [2]

That does not make the 2026 action unimportant. The regulatory problem was that the warning could be overlooked or misunderstood.

Patients and families told the Expert Working Group that important safety information was buried within long PILs, that the timing and meaning of the risk were not always clear, and that written information was not always reinforced by follow-up and clinical discussion. These views were considered alongside the scientific evidence; they were not automatically treated as proof of causation or of a particular risk magnitude. [2]

The resulting intervention therefore emphasises prominence, accessibility and actionability. The new PIL box is intended to direct patients and carers to the relevant warning, while the patient card provides concise information that can remain accessible after the medicine pack or leaflet is no longer immediately available.

The UK PIL box is not an FDA boxed warning

The phrase “boxed warning” can easily create confusion.

The US Food and Drug Administration uses Boxed Warnings in prescribing information as a specific regulatory labelling construct. Antidepressant labelling in the United States includes boxed-warning language addressing suicidal thoughts and behaviours in younger patients. [5]

The 2026 MHRA measure is different. It is a boxed warning within UK patient information leaflets to improve prominence and signposting. The MHRA Public Assessment Report explicitly discussed that US boxed warnings have a specific place in the US regulatory framework and do not have a direct equivalent legal basis in the UK. [2]

This distinction should be preserved in pharmacovigilance documentation and communication. Calling the UK measure a “black box warning” without qualification could incorrectly imply that the MHRA adopted the US regulatory construct.

Persistent Sexual Dysfunction and PSSD

Sexual dysfunction is a recognised adverse effect of several antidepressants. The more difficult issue is the persistence of symptoms after treatment is stopped.

The 2026 review uses the term post-SSRI sexual dysfunction (PSSD) because that is the term used by some affected patients and in parts of the literature. However, the MHRA also notes important limitations. Persistent symptoms have been reported with antidepressants beyond SSRIs, may include a range of sexual and non-sexual symptoms, and the magnitude of risk remains uncertain. [1,2]

The Public Assessment Report describes the evidence base as limited. It notes that there is no specific PSSD diagnosis in ICD-11 or DSM-5 and that available studies differ in populations, definitions, outcome ascertainment and study design. The MHRA therefore did not present a precise incidence estimate applicable to all patients. [2]

This is a good example of why regulatory wording must balance recognition of a serious patient experience with uncertainty about frequency, predictors and mechanism.

The practical message is not that every patient taking an antidepressant faces a known quantified probability of persistent sexual dysfunction. It is that persistent symptoms are sufficiently credible and clinically important to warrant clearer information, discussion and reporting, while further research remains necessary.

Which Antidepressants Are Affected by the PSSD Wording?

The MHRA Drug Safety Update lists the antidepressants for which healthcare professionals should discuss the possibility that sexual dysfunction may continue after treatment: citalopram, escitalopram, duloxetine, fluvoxamine, fluoxetine, paroxetine, sertraline, venlafaxine, amitriptyline and nortriptyline. [1]

This list should not be confused with the wider set of 28 antidepressants reviewed by the Expert Working Group. The review was broad, but the persistent-sexual-dysfunction wording is targeted to medicines with existing relevant warnings and additional medicines identified during the review as having a potential association. [2]

For MAHs, this creates a straightforward but important traceability requirement: implementation should be based on the regulator-approved wording and the affected product set, not on a blanket assumption that every antidepressant requires identical PSSD language.

Patient and Family Evidence as a Regulatory Input

One of the most important features of the review was the structured inclusion of patient and family experience.

Patients and families described difficulty locating warnings in PILs, concerns about the timing of risk discussions, experiences of persistent sexual symptoms, and uncertainty about where to seek help. The MHRA also worked with the Patients Association to test revised wording in people with a range of mental-health conditions. [2,4]

This does not mean that anecdotal experience replaced epidemiology. The Public Assessment Report repeatedly distinguishes stakeholder experience from the scientific literature review and from the CHM's final advice.

For pharmacovigilance, the useful principle is that different evidence sources answer different questions.

Evidence source What it can contribute
Spontaneous reports Clinical descriptions, unexpected patterns, seriousness, chronology and hypotheses
Patient/family experience Whether warnings are noticed, understood and usable in real life
Clinical trials Controlled estimates of certain treatment-emergent risks within trial populations
Observational data Risk magnitude, modifiers, long-term outcomes and real-world patterns
Literature Published case descriptions, epidemiology, mechanisms and comparative evidence
User testing/focus groups Whether wording and format communicate what regulators intend
Post-implementation studies Whether a risk-minimisation measure changes awareness, behaviour or outcomes

A strong safety decision does not collapse these sources into one evidence hierarchy. It asks what each source is capable of establishing and where uncertainty remains.

Risk-Minimisation Measures Introduced or Strengthened

Boxed warning in the patient information leaflet

The new box is intended to make information on thoughts of self-harm and suicidal behaviour more prominent and direct patients to the relevant section of the PIL. [1,2]

The measure addresses a recognised human-factors problem: information that is technically present may still fail if users cannot find it when needed.

From an MAH perspective, implementation requires more than inserting text. Approved wording needs to be reflected consistently in controlled product information, artwork, packaging workflows where applicable, national implementation processes and change-control records.

Patient card

The MHRA describes a new portable patient card intended to reinforce key messages and provide information about where to seek help. The card is expected to be available digitally and in hard copy. [1,2]

Patient cards are a familiar pharmacovigilance tool, but their effectiveness cannot be assumed. Relevant questions include:

These are the same principles that apply to other additional risk-minimisation materials: distribution is an implementation measure; effective risk minimisation requires evidence that the intervention works as intended.

Safety ancillary leaflet

A broader safety leaflet is planned for 2027. It is intended to support discussion of benefits, risks and treatment alternatives at the first consultation for new patients or at a subsequent consultation for existing patients. [1,2]

This is operationally significant because it moves some safety communication earlier in the treatment pathway. A PIL reaches the patient with the medicine; an ancillary leaflet delivered during clinical discussion can support informed decision-making before or during prescribing.

Alignment across the healthcare system

The MHRA is also coordinating with NICE, the British National Formulary and professional organisations to improve consistency of messages. The Public Assessment Report notes, for example, that BNF monitoring wording was changed so that monitoring was no longer described as conditional. [2]

For pharmacovigilance, consistency matters because contradictory advice can weaken otherwise well-designed risk minimisation. A patient may encounter the product leaflet, clinician advice, pharmacy information, NHS material and professional guidance. The system works best when these sources reinforce rather than undermine one another.

A Risk-Minimisation Lifecycle

The 2026 antidepressant action can be understood as a lifecycle:

  1. Recognise the risk. Suicidal thoughts/behaviours and persistent sexual dysfunction are identified in the existing safety framework.
  2. Identify a communication problem. Patients and families report that warnings may not be sufficiently visible, understandable or actionable.
  3. Review evidence. The regulator examines literature, reports, regulatory history and stakeholder experience.
  4. Design interventions. PIL wording, a boxed signpost, patient card and ancillary material are proposed.
  5. User-test the communication. Patients review wording and format.
  6. Implement across the system. Product information and supporting healthcare communications are aligned.
  7. Monitor effectiveness. Pharmacovigilance data and observational research are used to determine whether the intervention has the intended effect.
  8. Adapt if necessary. If communication remains ineffective or new evidence changes the safety picture, further action may be needed.

This lifecycle connects directly with QPPV.com's broader coverage of additional risk-minimisation measures, patient alert cards and risk-minimisation effectiveness evaluation.

Effectiveness Monitoring: Why the Intervention Is Not Finished at Publication

The Expert Working Group and CHM supported further research using the Clinical Practice Research Datalink (CPRD). The Public Assessment Report describes proposed work to improve understanding of suicidal thoughts and behaviours, persistent sexual dysfunction and potential risk factors, and to provide a framework for monitoring the effect of regulatory actions. [2]

This is a central pharmacovigilance lesson. A new warning is an intervention, not an endpoint.

Effectiveness can be considered at more than one level.

Process measures

Process measures ask whether the intervention was implemented.

Examples include:

Knowledge and behaviour measures

These ask whether the intervention changes understanding or actions.

Examples include:

Clinical or safety outcomes

These ask whether the intervention changes outcomes, while recognising that causal interpretation can be difficult.

Examples might include patterns of self-harm-related healthcare contacts, treatment discontinuation, help-seeking, Yellow Card reporting, or persistent sexual dysfunction diagnoses and management.

No single measure proves effectiveness. Increased reporting after a communication may reflect greater awareness rather than a true increase in incidence. A reduction in prescribing could represent more appropriate selection or unintended avoidance of beneficial treatment. Outcome interpretation therefore requires context.

Pharmacovigilance Implications for Marketing Authorisation Holders

The 2026 measures create several practical responsibilities for MAHs with affected products.

Product-information implementation

The approved changes need to be incorporated through the applicable regulatory route and maintained in controlled product information.

Version control should allow the organisation to show:

Safety-database and signal context

The communication change does not require every historical report to be reclassified. However, teams assessing new cases should understand the current regulatory context.

Reports of persistent sexual dysfunction should capture clinically relevant chronology, including onset during treatment, persistence after discontinuation, duration, phenotype of symptoms, concomitant medicines, relevant medical and psychiatric history, dechallenge information and any attempted treatment.

Reports involving suicidal thoughts or behaviours require careful assessment of chronology, indication, underlying disease, dose changes, withdrawal, concomitant treatment and other potential contributors. The existence of a warning does not establish causality in an individual case.

Literature surveillance

Because the MHRA identified important evidence gaps, literature monitoring remains particularly relevant. New epidemiological studies, diagnostic proposals, mechanistic research and treatment-outcome studies could materially alter understanding of persistent sexual dysfunction.

Aggregate assessment

PSUR/PBRER and signal-management processes should interpret emerging information in light of the current label and risk-minimisation strategy. A known risk can still generate new pharmacovigilance questions: frequency, susceptible populations, severity spectrum, reversibility, preventability and effectiveness of current controls.

QPPV oversight

For a QPPV organisation, the issue is broader than confirming that a variation was submitted.

Oversight should ask:

This is where product information, pharmacovigilance operations, medical affairs, regulatory affairs and quality systems meet.

Common Interpretation Errors

“The MHRA discovered PSSD in 2026”

That is inaccurate. The October 2026 action strengthens communication of persistent sexual dysfunction that was already recognised in relevant product information and had been reviewed previously. The review also formalised the use of the term PSSD in relevant PILs and highlighted continuing evidence gaps. [1,2]

“All antidepressants now carry a PSSD warning”

The review covered 28 antidepressants, but the persistent-sexual-dysfunction wording applies to a defined subset of medicines associated with the risk. [1,2]

“The MHRA introduced the same black box warning as the FDA”

No. The MHRA introduced a boxed warning in the patient information leaflet to improve prominence and signposting. The FDA Boxed Warning is a distinct US prescribing-information construct with a specific regulatory role. [2,5]

“A boxed warning proves the risk is common”

Prominence does not establish frequency. The purpose of a risk-minimisation warning is to communicate an important risk in a way that supports safe use. The MHRA specifically notes uncertainty about the magnitude of persistent sexual dysfunction. [2]

“Once the leaflet is updated, risk minimisation is complete”

No. The 2026 programme includes patient cards, wider communication, a future ancillary leaflet and effectiveness monitoring. The intervention must be assessed in practice.

Practical Checklist for PV and Regulatory Teams

When implementing or overseeing the 2026 UK antidepressant measures, a practical review should confirm:

The exact controls depend on the MAH's products, systems and applicable regulatory obligations. This checklist is operational guidance, not a substitute for the approved product information or MHRA instructions.

Broader Lessons for Pharmacovigilance

The antidepressant review illustrates several principles that apply well beyond psychiatry.

First, known risk does not mean solved risk. A safety concern can be correctly labelled yet poorly communicated.

Second, patients are evidence partners in risk minimisation. They can reveal failures in comprehension, timing, accessibility and usability that are difficult to detect from spontaneous-report counts alone.

Third, risk communication should be treated as an intervention that requires evaluation. Printing or distributing material is not the same as reducing risk.

Fourth, regulatory language must preserve uncertainty. The MHRA acknowledges persistent sexual dysfunction while also acknowledging major uncertainty about frequency, determinants and mechanism.

Fifth, cross-system consistency matters. Product information, clinical guidance, pharmacy practice and patient materials should reinforce one another.

Finally, pharmacovigilance continues after the communication is issued. Reporting, literature surveillance, observational research and formal effectiveness evaluation determine whether the next regulatory step is no change, refinement, escalation or withdrawal of an ineffective measure.

Key Takeaways

The MHRA's October 2026 antidepressant action is best understood as a risk-minimisation redesign.

The recognised risks of suicidal thoughts and behaviours and persistent sexual dysfunction were not newly discovered in 2026. The regulatory change is that the MHRA judged stronger and more accessible communication to be necessary after a detailed review involving patients, families, experts and scientific evidence.

The new UK measures combine a boxed PIL signpost, patient card, revised persistent-sexual-dysfunction wording, a planned ancillary safety leaflet and wider healthcare-system alignment. The UK PIL box should not be confused with the FDA's Boxed Warning construct.

Persistent sexual dysfunction remains an area of important uncertainty. The MHRA recognises the potential for symptoms to continue after treatment and is adding the term PSSD to relevant PILs, but it also states that the evidence base does not support a robust general estimate of incidence.

For pharmacovigilance systems, the most important next question is whether the new measures work. Implementation, patient understanding, clinician behaviour, safety reporting and observational evidence all form part of the effectiveness assessment.

References

  1. Medicines and Healthcare products Regulatory Agency. Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction. Drug Safety Update. 15 October 2026. Available from: https://www.gov.uk/drug-safety-update/antidepressants-new-safety-measures-for-all-patients-to-improve-communication-of-the-risk-of-suicidal-thoughts-and-behaviours-and-persistent-sexual-dysfunction
  2. Medicines and Healthcare products Regulatory Agency. Antidepressants – updated safety communications: Public Assessment Report. Expert Working Group on Antidepressant Risk Minimisation Recommendations and Commission on Human Medicines Advice. 15 October 2026. Available from: https://www.gov.uk/government/publications/antidepressants-updated-safety-communications
  3. Medicines and Healthcare products Regulatory Agency. Antidepressants: use and safety. Updated 15 October 2026. Available from: https://www.gov.uk/government/publications/antidepressants-use-and-safety--2
  4. Medicines and Healthcare products Regulatory Agency. Patient and family experiences inform antidepressant safety information review. 1 December 2025. Available from: https://www.gov.uk/government/news/patient-and-family-experiences-inform-antidepressant-safety-information-review
  5. U.S. Food and Drug Administration. Antidepressant product labelling — suicidal thoughts and behaviours in children, adolescents and young adults. Current product-specific prescribing information is available through Drugs@FDA. Example current labelling accessed for regulatory comparison via: https://www.accessdata.fda.gov/drugsatfda_docs/label/

Regulatory Note

This article describes the UK regulatory position announced by the MHRA on 15 October 2026 and should not be generalised automatically to other jurisdictions. Product-specific implementation depends on the approved UK product information and applicable regulatory instructions. The term PSSD is used because the MHRA has incorporated it into relevant patient information, but the agency also emphasises uncertainty in the evidence base, including uncertainty around frequency, predictors and case definition. The UK patient-information boxed warning is distinct from the FDA Boxed Warning used in US prescribing information. Pharmacovigilance professionals should verify the current approved product information and subsequent MHRA updates before applying these measures operationally.

Revision History

QPPV.com